Supplementary Table: Summary of the clinical, pathological and molecular data of the MTC cases

|  |  |
| --- | --- |
|  | **MTC** |
| **Gender (n=54) \*** **Female** **Male** | 29 (53.7 %)25 (46.3%) |
| **Age (years) \***  **(n=54; mean ± S.D.)** | 53.6 (±14.1) |
| **Age (n=54) \*** **<45 years** **≥45 years** | 14 (25.9%)40 (74.1%) |
| **Tumor size (cm) \***  **(n=38; mean ± S.D.)** | 2.6 (±1.7) |
| **Tumor size (n=38) \*** **<2 cm** **≥2 cm** | 18 (47.4%)20 (52.6%) |
| **Stroma (n=71) \*** **Absent** **Present (hyaline)** | 20 (28.2%)51 (71.8%) |
| **Amyloid deposits (n=40) \*** **Absent** **Present** | 14 (35%)26 (65%) |
| **Invasion (vascular and/or capsular) (n=25) \*** **Absent** **Present** | 4 (16%)21 (84%) |
| **Extrathyroidal extension (n=21) \*** **Absent** **Present** | 7 (33.3%)14 (66.7%) |
| **Metastasis (lymph node and/or distant) (n=29) \*** **Absent** **Present** | 11 (37.9%)18 (62.1%) |
| ***RET* mutation (n=75)** **Absent** **Present** **- *germinative***  **- *somatic***  | 37 (49.3%)38 (50.7%)*7 (18.4%)**31 (81.6%)* |
| ***RAS* mutation (n=75)** **Absent** **Present** | 66 (88%)9 (12%) |
| **PTEN nucl. % cellular expression** **0%** **0-25%** **25-50%** **50-75%** **75-100%** | 30 (40%)18 (24%)9 (12%)8 (10.7%)10 (13.3%) |
| **PTEN citopl. % cellular expression** **0%** **0-25%** **25-50%** **50-75%** **75-100%** | 4 (5.3%)6 (8%)4 (5.3%)9 (12%)52 (5%) |
| **pS6 % cell. expression** **0%** **0-25%** **25-50%** **50-75%** **75-100%** | 11 (14.7%)8 (10.7%)-10 (13.3%)46 (61.3%) |
| **OPN % cell. expression\*** **<5%** **5-25%** **25-50%** **50-75%** **75-100%**  | 13 (17.3%)3 (4%)14 (18.7%)8 (10.7%)34 (45.3%) |

\*Some clinicopathological/immunohistochemical features were not available for all the cases